Image of Jessica Delbaum

Jessica Delbaum

Partner

Email

Jessica.Delbaum@aoshearman.com

Phone

+1 212 848 4815

Offices

New York

Links

LinkedIn

V-CARD
Jessica focuses on defending multi-national companies’ mergers and acquisitions before the Federal Trade Commission and the Department of Justice as well as coordinating the multi-jurisdictional antitrust defense of transactions. She also counsels clients on an extensive array of antitrust issues such as competitor collaborations, cartel leniency applications and Hart-Scott-Rodino Act compliance, including integration planning.

Jessica has also defended substantive merger investigations involving a wide variety of industries, including agriculture, pharmaceuticals, medical devices, biotechnology, media, aviation, technology, chemicals and finance.

After graduating from law school, Jessica was an Attorney General’s Honors Program Attorney in the Antitrust Division of the Department of Justice. While at the Division, she investigated possible violations of the antitrust laws involving mergers and acquisitions, the reporting and waiting requirements of the Hart-Scott-Rodino Act and civil price-fixing.

Jessica is a Chambers-ranked practitioner, and her practice has also been recognized by various other publications including Legal 500. In 2021, Jessica was named to The BTI Consulting Group’s Client All-Stars List, a rare client-designated honor for excellence in client service as reflected in a survey of corporate America’s top decision makers.

Jessica is a regular speaker on a variety of antitrust-related topics.

Expertise

Industries

Experience

Representative matters

  • Exscientia, a UK based pharmatech company, on its proposed combination with Recursion, a U.S. based technology-enabled biotech company.
  • Atrion Corporation in its merger with Nordson Corp.
  • JetBlue Airways on its proposed acquisition of Spirit Airlines and in its Northeast Alliance with American Airlines.
  • Paramount in its sale of Simon & Schuster to KKR (as well as its proposed sale to Penguin Random House) and in its sale of C|NET to Red Ventures.
  • Carbon Engineering in its sale to Occidental Petroleum Corporation.
  • Dover Corporation in its acquisition of FW Murphy Production Controls and in its acquisition of Belanger, Inc.
  • invoX Pharma, a wholly owned subsidiary of Sino Biopharmaceutical Limited, in connection with its tender offer for F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company.
  • Sun Pharmaceutical in its acquisitions of Ocular Technologies, Ranbaxy Laboratories, Pharmalucence Inc., URL Pharma, DUSA Pharmaceutical and Taro Pharmaceutical and in its acquisition of Odomzo from Novartis and its licensing agreement with Cassiopea for Winlevi, its licensing agreement with Aché Laboratórios for Existing Ach24 Extract, and its licensing agreement with Merck for MK-3222.
  • Glatfelter in its acquisition of the Jacob Holm Group, a global leading manufacturer of premium quality spunlace nonwoven fabrics; in its acquisition of Georgia-Pacific’s U.S. nonwovens business and its acquisition of Georgia-Pacific’s European nonwovens business and in its sale of its Specialty Paper Business to Lindsey Goldberg.
  • Bunge in its sale of certain grain elevators to Zen-Noh Corporation and in its acquisition of a state-of-the-art refinery from Fuji Oil and in its acquisition of Loders.
  • Lanxess on its acquisition of Emerald Kalama Chemical.
  • Amneal Pharmaceuticals in its acquisition of Kashiv Specialty Pharmaceuticals, LLC. 
  • Virbac sale of Sentinel veterinary products to MSD Animal Health, a division of Merck & Co.
  • Canada Pension Plan Investment Board (CPPIB) in its acquisition of Pattern Energy Group Inc. (Pattern Energy) and its agreement with Riverstone Holdings LLC to subsequently combine Pattern Energy with Pattern Energy Group Holdings 2 LP.
  • Telus International in its acquisition of Competence Call Center.
  • Brentwood/Credentials Solutions in the acquisition of Parchment.
  • Vice Media in its acquisition of Refinery 29.
  • Thomson Reuters in its acquisition of Confirmation.
  • Salesforce in its acquisitions of MapAnything and Click Software.
  • GSK in its acquisition of oncology-focused biopharmaceutical company Tesaro.
  • LyondellBasell in its acquisition of A. Schulman, Inc.
  • Bojangles in its merger with Walker Parent.
  • Sonic Corporation in its sale to Inspire Brands.
  • Intapp in its acquisition of DealCloud.
  • SS&C in its acquisition of Eze Software.
  • KMG Chemicals in its acquisition by Cabot Microelectronics.
  • Bridgepoint in its sale of Pret-a-Manger to JAB Holdings and its acquisition of Element Materials Technology.
  • Shiseido in its sale of its subsidiary Zotos to Henkel.
  • Hoya in its acquisition of Performance Optics.
  • American Axle in its acquisition of Metaldyne Performance Group.
  • B/E Aerospace in its sale to Rockwell Collins.
  • Fairfax in its acquisition of Allied World.
  • Pall Corporation in its sale to Danaher Corporation and in its acquisition of ATMI’s LifeSciences business.
  • CX Partners and Capital Square Partners on the sale of Minacs to Concentrix Global Holdings Inc.
  • Corning in its acquisition of Alliance Fiber Optic Products, Inc.
  • Investcorp in its €1 billion sale of Icopal a/s to GAF, North America’s largest roofing manufacturer.
  • Nokia on its sale of HERE to an automotive industry consortium.
  • Wausau Paper Corporation in its acquisition by SCA.
  • Individual in relation to cartel investigation by the U.S. Department of Justice.
  • Major Asian industrial company in relation to non-public cartel investigations by the U.S. Department of Justice and other antitrust agencies.
  • Fortune 200 company in an internal investigation related to pricing practices.

Published Work

  • Delbaum, Jessica, Co-author. (2024) “DOJ Seeks Rare $3.5M ‘Gun Jumping’ Penalty Against Legends Hospitality for Pre-Closing Conduct in Connection with Acquisition of ASM Global,” The M&A Lawyer
  • Delbaum, Jessica, Co-author. (2022) Mergers & Acquisitions in Antitrust Adviser (6th ed.)
  • Delbaum, Jessica, Co-author. (2014, 2020, 2022) “Merger Remedies in the US: An Overview of the Leading Cases,” Concurrences
  • Delbaum, Jessica, Co-author. (2020) Merger Remedies, United States, Global Competition Review
  • Delbaum, Jessica, Co-author. (2020) “Edgewell/Harry’s: When a Maverick is More Than Its Market Share,” The M&A Lawyer
  • Delbaum, Jessica, Co-author. (2017-19) “United States: Cartels” for The Americas Antitrust Review, Global Competition Review
  • Delbaum, Jessica, Co-author. (2016-19) “IP & Antitrust Know-How,” Global Competition Review
  • Delbaum, Jessica, Co-author. (2010) “Strategic Deals Require Strategic Thinking: Antitrust Provisions to Consider in Negotiated Transactions,” The M&A Lawyer

Speaking Engagements

  • Jessica is a regular speaker on a variety of antitrust-related topics.

Leadership Positions And Professional Affiliations

  • Member, American Bar Association Antitrust Law Section
  • Member, Executive Committee, New York State Bar Association Antitrust Law Section

Recognition

“Jessica is a pleasure to work with. She is very responsive, knowledgeable and also very commercial.”
Chambers USA, 2023
“She has an incredible mind, she’s very helpful and very pragmatic. She’s fantastic.”
Chambers USA, 2022

Awards

  • Ranked by Legal 500 and Chambers USA
  • Recognized in the BTI Consulting Group’s Client All-Stars List
  • Featured in Who’s Who Legal Competition List
  • Recognized as a New York “Super Lawyer” for antitrust

Qualifications

Admissions

Attorney-at-Law, New York

United States Supreme Court

Courts

United States District Court for the Eastern District of New York

United States District Court for the Southern District of New York

Academic

B.A. (Economics-Philosophy), magna cum laude, Columbia College

J.D., cum laude, Harvard University

Articles Editor, International Law Journal

Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.